Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) EBIT Margin (2022 - 2025)

Arcutis Biotherapeutics has reported EBIT Margin over the past 4 years, most recently at 14.65% for Q4 2025.

  • Quarterly results put EBIT Margin at 14.65% for Q4 2025, up 2565.0% from a year ago — trailing twelve months through Dec 2025 was 3.3% (up 6270.0% YoY), and the annual figure for FY2025 was 3.29%, up 7381.0%.
  • EBIT Margin for Q4 2025 was 14.65% at Arcutis Biotherapeutics, up from 8.59% in the prior quarter.
  • Over the last five years, EBIT Margin for ARQT hit a ceiling of 14.65% in Q4 2025 and a floor of 14448.0% in Q3 2022.
  • Median EBIT Margin over the past 4 years was 105.15% (2023), compared with a mean of 1551.45%.
  • Biggest five-year swings in EBIT Margin: skyrocketed 1432499bps in 2023 and later surged 2537bps in 2025.
  • Arcutis Biotherapeutics' EBIT Margin stood at 2310.84% in 2022, then surged by 80bps to 452.23% in 2023, then skyrocketed by 98bps to 11.0% in 2024, then soared by 233bps to 14.65% in 2025.
  • The last three reported values for EBIT Margin were 14.65% (Q4 2025), 8.59% (Q3 2025), and 17.93% (Q2 2025) per Business Quant data.